title: Quantitative analysis of the heteromeric neuronal nicotinic receptors in the rat hippocampus.
abstract: The objective of this study was to identify and quantify the heteromeric neuronal nicotinic receptors (nAChRs) in the rat hippocampus. The density of nAChR subtypes was assessed by labeling them with [(3)H]epibatidine ([(3)H]EB) followed by immunoprecipitation with subunit-selective antibodies. Sequential immunoprecipitation assays were used to establish associations between two different subunits, which then allowed the full subunit composition of the receptors to be deduced. Our results show that most of the hippocampal heteromeric nAChRs contain α4 and β2 subunits. In fact, we identified two populations containing these two predominant subunits, the α4β2 and α4β2α5 subtypes which account for ∼ 40% and ∼ 35%, respectively, of the total [(3)H]EB-labeled receptors. An additional heteromeric subtype with the subunit composition of α4β2α3 represented ∼ 10% of the total nAChRs, and another 10% of the immunoprecipitated receptors contained α4 and β4 subunits, with or without the α3 subunit. To determine if α4β2 and α4β2α5 nAChR subtypes differ in their ligand binding affinities, the α3- and β4-containing receptors were first removed by immunoprecipitation and then, competition studies with acetylcholine, nicotine, cytisine and sazetidine-A against [(3)H]EB were carried out on the remaining α4β2 and α4β2α5 subtypes. Results suggested these subtypes have comparable binding affinities for the nicotinic ligands used here.
authors.affiliation: Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20057, USA.
authors.forename: Ermelinda
authors.initials: E
authors.lastname: Lomazzo
authors.forename: Linda
authors.initials: L
authors.lastname: MacArthur
authors.forename: Robert P
authors.initials: RP
authors.lastname: Yasuda
authors.forename: Barry B
authors.initials: BB
authors.lastname: Wolfe
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Kellar
mesh_terms: D000818:Animals; D001667:Binding, Competitive / Q000502:physiology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism*; D047468:Immunoprecipitation; D008024:Ligands; D008297:Male; D018722:Nicotinic Agonists / Q000378:metabolism; D011725:Pyridines / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000378:metabolism*
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; C499978:Chrna5 protein, rat; D008024:Ligands; D018722:Nicotinic Agonists; D011725:Pyridines; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; C082748:epibatidine
references.citation: J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):806-9
references.pmid: 2956364
references.citation: Mol Pharmacol. 2006 Oct;70(4):1454-60
references.pmid: 16857741
references.citation: Br J Pharmacol. 1996 Feb;117(4):595-606
references.pmid: 8646402
references.citation: Neuroscience. 1983 Dec;10(4):1185-201
references.pmid: 6320048
references.citation: J Biol Chem. 1990 Mar 15;265(8):4472-82
references.pmid: 1689727
references.citation: J Chem Neuroanat. 2006 Dec;32(2-4):179-90
references.pmid: 17046198
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3517-25
references.pmid: 19029397
references.citation: Trends Pharmacol Sci. 2004 Jun;25(6):317-24
references.pmid: 15165747
references.citation: J Neurochem. 2008 Jan;104(2):446-56
references.pmid: 17961152
references.citation: J Pharmacol Exp Ther. 1998 Jul;286(1):311-20
references.pmid: 9655874
references.citation: J Pharmacol Exp Ther. 2004 Jul;310(1):98-107
references.pmid: 15016836
references.citation: J Pharmacol Exp Ther. 1993 Jun;265(3):1455-73
references.pmid: 8510022
references.citation: Mol Pharmacol. 1998 Dec;54(6):1132-9
references.pmid: 9855644
references.citation: Neuroscience. 2004;124(4):817-22
references.pmid: 15026122
references.citation: Biophys J. 1991 Sep;60(3):721-7
references.pmid: 1718469
references.citation: Mol Psychiatry. 2008 Apr;13(4):368-73
references.pmid: 18227835
references.citation: J Physiol. 2002 Apr 15;540(Pt 2):425-34
references.pmid: 11956333
references.citation: J Comp Neurol. 2008 Nov 10;511(2):286-99
references.pmid: 18792073
references.citation: J Comp Neurol. 1989 Jun 8;284(2):314-35
references.pmid: 2754038
references.citation: Nature. 1996 Mar 28;380(6572):347-51
references.pmid: 8598930
references.citation: J Pharmacol Exp Ther. 1991 Sep;258(3):1127-36
references.pmid: 1890617
references.citation: J Pharmacol Exp Ther. 1997 Jan;280(1):346-56
references.pmid: 8996215
references.citation: J Neurochem. 2001 Jun;77(6):1581-9
references.pmid: 11413241
references.citation: J Neurochem. 2001 Oct;79(2):258-65
references.pmid: 11677253
references.citation: Neuron. 1992 Oct;9(4):679-91
references.pmid: 1389183
references.citation: Hum Mol Genet. 2007 Jan 1;16(1):36-49
references.pmid: 17135278
references.citation: J Neurochem. 1996 Nov;67(5):1953-9
references.pmid: 8863500
references.citation: J Neurosci. 1999 Apr 15;19(8):2887-96
references.pmid: 10191306
references.citation: Mol Pharmacol. 1992 Jan;41(1):31-7
references.pmid: 1732720
references.citation: Addiction. 2008 Sep;103(9):1544-52
references.pmid: 18783506
references.citation: Mol Pharmacol. 1994 Jan;45(1):142-9
references.pmid: 8302273
references.citation: Eur J Neurosci. 2009 Apr;29(8):1588-603
references.pmid: 19385992
references.citation: Proc Natl Acad Sci U S A. 1987 Jan;84(2):595-9
references.pmid: 3467376
references.citation: J Physiol. 2000 Sep 15;527 Pt 3:515-28
references.pmid: 10990538
references.citation: J Neurosci. 1991 Mar;11(3):837-45
references.pmid: 1705971
references.citation: J Neurosci. 1998 Nov 1;18(21):8571-9
references.pmid: 9786965
references.citation: Ann Neurol. 1982 Nov;12(5):494
references.pmid: 7181455
references.citation: Trends Pharmacol Sci. 2006 Sep;27(9):482-91
references.pmid: 16876883
references.citation: J Physiol. 1999 May 1;516 ( Pt 3):657-78
references.pmid: 10200416
references.citation: Neuroscience. 2003;119(4):965-77
references.pmid: 12831856
references.citation: Mol Pharmacol. 2004 Oct;66(4):978-87
references.pmid: 15247319
references.citation: Prog Brain Res. 2004;145:109-20
references.pmid: 14650910
references.citation: Mol Pharmacol. 2002 Jun;61(6):1416-22
references.pmid: 12021403
references.citation: Mol Pharmacol. 2007 Mar;71(3):769-76
references.pmid: 17132685
references.citation: J Pharmacol Exp Ther. 2007 Jul;322(1):306-15
references.pmid: 17446303
references.citation: J Neurosci. 2005 Oct 5;25(40):9258-65
references.pmid: 16207885
references.citation: Neuroreport. 1997 Jul 28;8(11):2433-6
references.pmid: 9261804
references.citation: Neuron. 1989 Nov;3(5):589-96
references.pmid: 2484342
references.citation: Mol Pharmacol. 2005 Dec;68(6):1656-68
references.pmid: 16129735
references.citation: J Biol Chem. 1991 Dec 5;266(34):23354-64
references.pmid: 1744130
references.citation: Clin Cancer Res. 2009 Mar 1;15(5):1837-42
references.pmid: 19223495
references.citation: J Biol Chem. 1989 Jul 25;264(21):12666-72
references.pmid: 2568359
references.citation: J Neurosci. 1992 Dec;12(12):4611-23
references.pmid: 1464760
references.citation: Mol Pharmacol. 2006 Nov;70(5):1693-9
references.pmid: 16882879
references.citation: Am J Psychiatry. 2008 Sep;165(9):1163-71
references.pmid: 18519524
references.citation: J Physiol. 1997 Nov 1;504 ( Pt 3):603-10
references.pmid: 9401968
references.citation: J Biol Chem. 1996 Jul 26;271(30):17656-65
references.pmid: 8663494
references.citation: J Neurosci. 2009 Jan 28;29(4):918-29
references.pmid: 19176801
references.citation: J Physiol. 1997 Apr 1;500 ( Pt 1):123-38
references.pmid: 9097938